Fluoxetine

證據等級: L5

預測適應症: 10 個

Fluoxetine: From Depression to Schizotypal Personality Disorder

One-Sentence Summary

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI), internationally approved and widely used for major depressive disorder, obsessive-compulsive disorder, and bulimia nervosa, though it carries no active Singapore registration. The TxGNN model predicts it may be effective for Schizotypal Personality Disorder, with 0 clinical trials and 11 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	No Singapore registration (internationally: major depressive disorder, OCD, bulimia nervosa)
Predicted New Indication	Schizotypal Personality Disorder
TxGNN Prediction Score	99.92%
Evidence Level	L3
Singapore Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the source system. Based on known pharmacological information, Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) whose antidepressant and anxiolytic efficacy has been established over decades of clinical use across depression, OCD, panic disorder, and eating disorders.

As an SSRI, Fluoxetine enhances synaptic serotonin transmission by blocking the serotonin transporter (SERT), thereby increasing serotonin availability in the prefrontal cortex, amygdala, and striatum. In schizotypal personality disorder, this mechanism could theoretically reduce anxiety-driven hypervigilance, compulsive and ritualistic behaviors, and the mild perceptual distortions that characterize the condition. The serotonin–dopamine imbalance hypothesis — which posits that dysregulated serotonergic modulation of dopaminergic pathways underlies schizotypal symptoms — provides the key mechanistic bridge.

The most direct evidence comes from a 12-week open-label trial (Markovitz et al., 1991) enrolling 22 patients with borderline or schizotypal personality disorder, which found significant reductions in self-injurious behavior and Hopkins Symptom Checklist scores regardless of diagnosis. Subsequent narrative reviews of cluster A personality disorder pharmacotherapy suggest SSRIs may address anxiety and impulsivity components, but underline that core schizotypal features (cognitive-perceptual distortions, odd thinking) may require low-dose antipsychotic augmentation. Large-scale randomized controlled evidence is entirely absent, and a cautionary case report (PMID 9664779) documents transient psychosis in a schizotypal patient taking fluoxetine — warranting careful monitoring if this pathway is pursued.

Clinical Trial Evidence

Currently no related clinical trials registered for Fluoxetine specifically in Schizotypal Personality Disorder.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1853957	1991	Open-label Trial	Am J Psychiatry	22 patients with borderline/schizotypal PD; significant reductions in self-injury and symptom scores (Hopkins Symptom Checklist) with 12 weeks of fluoxetine; authors call for controlled trials
9448667	1998	Prospective Observational	J Clin Psychiatry	Reviews psychopharmacology of borderline and schizotypal PD; no single agent of choice identified; SSRIs among agents showing benefit for selected symptom clusters
29955451	2016	Narrative Review	Ment Health Clin	Pharmacotherapy review for cluster A PDs (paranoid, schizoid, schizotypal); summarizes available evidence including SSRIs, antipsychotics, and mood stabilizers
8227492	1993	Conceptual Review	J Clin Psychopharmacol	Conceptual framework for PD pharmacotherapy; discusses SSRI utility for impulsive-affective symptom dimension relevant to schizotypal PD
12214786	2002	Review	Psychol Med	PD diagnoses assessed before and after fluoxetine in depressed outpatients; explores whether PD stability changes with antidepressant treatment
9664779	1998	Case Report	Psychosomatics	⚠️ Adverse event: transient psychosis with psychogenic polydipsia in a schizotypal patient on fluoxetine — highlights risk of symptom exacerbation
7635854	1995	RCT	J Clin Psychiatry	Predictors of drug response in OCD; schizotypal comorbidity found to predict poorer treatment response to serotonergic agents
15209835	2004	Cohort	Aust NZ J Psychiatry	Personality traits and treatment outcome in bipolar II vs. major depression; indirect background on personality-treatment interactions
33634761	2021	Case Report	CNS Neurol Disord Drug Targets	Catatonia in a patient with schizotypal PD treated with asenapine; illustrates clinical complexity of psychopharmacology in this population
18805590	2009	Cohort	J Affect Disord	18-month depression relapse predictors; schizotypal PD comorbidity associated with poorer depression outcomes under antidepressant treatment

Singapore Market Information

Fluoxetine currently holds no product registrations with the Health Sciences Authority (HSA) of Singapore. No authorizations are on record.

Note: Fluoxetine is internationally approved in numerous jurisdictions (FDA, EMA, TGA) under brand names including Prozac and Sarafem, with established indications for major depressive disorder, OCD, panic disorder, and bulimia nervosa. Its absence from the Singapore registry does not reflect global regulatory standing.

Safety Considerations

Please refer to the package insert for safety information, as Singapore-specific warnings and contraindications are not available in the current data.

Specific caution for this repurposing context: One case report (PMID 9664779) documents transient psychosis in a schizotypal patient receiving fluoxetine. Given that schizotypal personality disorder lies on the schizophrenia spectrum, any trial of SSRIs in this population should include baseline and ongoing assessment of psychotic symptom burden, with low starting doses and concurrent clinical monitoring.

Conclusion and Next Steps

Decision: Hold

Rationale: Current evidence for Fluoxetine in schizotypal personality disorder reaches only L3 — a single 22-patient open-label study and several narrative reviews — with no registered clinical trials and an adverse event signal (psychosis induction) that cannot be dismissed without controlled data. This is a scientific hypothesis worth pursuing, not a repurposing candidate ready for clinical action.

To proceed, the following is needed:

Retrieval and review of full Fluoxetine prescribing information (safety warnings, contraindications, pregnancy category) from an authoritative source such as FDA label or EMA SmPC
Drug interaction profile (DDI data not found in current query)
At least one prospective, controlled pilot trial specifically targeting schizotypal personality disorder symptoms (particularly anxiety, cognitive-perceptual, and impulsivity dimensions)
Clarification of whether benefit is specific to schizotypal PD or secondary to comorbid depression/anxiety — a dedicated diagnostic sub-analysis is needed
Risk stratification protocol for psychosis monitoring if a future trial is initiated
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.